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TO THE EDITOR
Neutrophilic dermatoses (NDs) are char-
acterized by dense infiltrates of mature
neutrophils typically located in the
upper dermis. Despite having dissimilar
clinical presentations, Sweet’s syn-
drome, pyoderma gangrenosum, neutro-
philic eccrine hidradenitis, and other
related disorders are recognized as part
of the spectrum of NDs because of their
overlapping clinical and histopatho-
logical findings (Vignon-Pennamen
and Wallach, 1991). Although most
instances of ND have a benign course,
some extracutaneous localizations
of the neutrophilic infiltrates can be
potentially life-threatening (Vignon-
Pennamen, 2000).
Little is known about the patho-
physiology of ND. The findings of high
CD3, IL-1, IL-8, and tumor necrosis
factor-a expressions by immunohisto-
chemical staining in the dermis of ND
patients (Marzano et al., 2010) and the
impressive effects of corticosteroids in
alleviating these diseases have under-
lined a role for activated T lymphocytes
in the recruitment of mature neutrophils
to the dermis. Moreover, targeted immu-
nosuppressive agents such as tumor
necrosis factor-a inhibitors and the
IL-1R inhibitor anakinra have been
successfully used in the treatment of
Sweet’s syndrome, which has further
emphasized the importance of these
cytokines in the pathophysiology of
ND (Yamauchi et al., 2006; Delluc
et al., 2008; Lipsker et al., 2010).
Around 20% of patients with
Sweet’s syndrome have an underlying
hematological malignancy, which is
predominantly a myeloid neoplasm
(Cohen et al., 1988). In these cases,
one could hypothesize that neutrophils
have differentiated from the malignant
clone, showing an aberrant phenotype,
which promotes dermal invasion. In this
model, neutrophils in the dermal
infiltrate should be clonally related to
the underlying myeloid malignancy,
which has never been formally demon-
strated to date.
We thus conducted a multicentric
retrospective study, which included 14
ND patients (8 men and 6 women)
with (1) a histopathological diagnosis
of Sweet’s syndrome (n¼ 12), pyoderma
gangrenosum (n¼1), or neutrophilic
eccrine hidradenitis (n¼ 1), and (2) a
diagnosis of myelodysplastic syndrome
(MDS, n¼2) or acute myeloid leukemia
(AML, n¼12), and with a medullar
cytogenetic abnormality that would
be informative in a fluorescent in situ
hybridization (FISH) study.
In two patients, the ND was present at
the initial presentation of AML. This
condition was chemotherapy-induced
in seven patients and occurred without
any identifiable trigger in four patients.
All patients but one were febrile when
the ND diagnosis was established, and
four patients had an extracutaneous
involvement (lung (n¼1), muscle
(n¼ 1), mouth (n¼ 2)), which is a much
higher frequency than what is reported
in idiopathic ND (Vignon-Pennamen,
2000). No patient had concomitant
neutrophil leukocytosis. Three patients
were profoundly neutropenic at the time
of ND occurrence. This observation
confirms that hyperleukocytosis is irrele-
vant as a diagnostic criterion for ND
associated with myeloid malignancies.
To test the hypothesis of a clonal
relationship between the skin-infiltrating
neutrophils and the bone marrow blasts,
the FISH study was conducted on 3mm
skin tissue sections processed using the
Histology FISH Accessory Kit (Dako,
Glostrup, Denmark). After hybridization
with specific probes (Table 1), scoring of
the hybridization signals was performed
on 200 consecutive morphologically
intact nuclei, with a normal cutoff value
evaluated at 10% (Haralambieva et al.,
2002). This approach was noninforma-
tive in three patients because of an
insufficient number of analyzable
nuclei. Among the other 11 patients
analyzed, 8 showed the same cyto-
genetic anomaly in the neutrophils infil-
trating the skin and in the bone marrow
(Figure 1), whereas there were no
evidence of any clonal cytogenetic
abnormality in the neutrophils of the
remaining three patients.
A previous study using a HUMARA
assay has found evidence of clonality in
the skin neutrophils of 80% of women
(median age 60 years) with ND, regard-
less of whether they had an underlying
Abbreviation: AML, acute myeloid leukemia; FISH, fluorescent in situ hybridization; MDS, myelodysplastic
syndrome; ND, neutrophilic dermatosis
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hematological malignancy (Magro et al.,
2007). However, the HUMARA assay is
no longer considered to be a reliable
test for clonality, especially in elderly
women (Busque et al., 1996; Swierczek
et al., 2012). To avoid this potential
bias, we utilized the FISH technique
to unambiguously reveal that skin-
infiltrating neutrophils arise from the
differentiation of the myeloid clone.
Nevertheless, FISH analysis of skin
specimens is very technically challen-
ging, partly because of the collagen
fibers that exhibit autofluorescence.
This may explain the failure of this
technique in three of our patients.
FISH analysis was previously used in
two case reports. van Kamp et al. (1994)
reported the presence of 5q- nuclei in
some cells of the cutaneous biopsy
of a patient with 5q- AML and ND.
Nevertheless, the histological descri-
ption of the lesion in this case was not
detailed enough to exclude the
possibility that the detected 5q- nuclei
did not correspond to blastic cells
infiltrating the dermis. In most of
our current patients, our histological
analysis revealed typical ND without
any detectable blastic cells by standard
colorations or by CD34 immunohisto-
chemical staining. In our only FISH-
positive patient who had a few blastic
cells in the infiltrate, we considered that
these cells were too few in number to
explain the large majority of nuclei that
were positive for the FISH abnormality.
More recently, Loon et al. (2012) demo-
nstrated with a FISH study a clonally
restricted neutrophilic infiltrate in a
single case of unusual neutrophilic
dermatosis of the mouth associated
with 20q- MDS, a result confirmed and
generalized by our present study.
Our present data show that in most
cases of ND, the skin-infiltrating
neutrophils that arise in the context of
myeloid malignancies have differen-
tiated from the malignant clone. For
patient 11, the Y loss could have been
an aging phenomenon (Wiktor et al.,
2000), but the high proportion of mitosis
with this anomaly and the normalization
of the karyotype when the patient
achieved complete remission with
induction chemotherapy argues for an
AML-related cytogenetic abnormality.
In the three remaining patients, ND
could be sustained by neutrophils that
have differentiated from residual normal
hematopoietic cells or from subclones
of the myeloid malignancy that were
below the threshold of detection, using
our experimental approach. This patho-
physiological explanation is consistent
with the striking clinical similarities
between Sweet’s syndrome and the
differentiation syndrome observed in
patients with acute promyelocytic leuke-
mia treated with retinoic acid, i.e., the
association with fever, multiorgan infil-
tration by neutrophils, and the marked
response to corticosteroids.
The occurrence of ND in three pro-
foundly neutropenic patients in our
Figure 1. Hematoxylin–eosin–saffron (HES) and fluorescent in situ hybridization (FISH) analyses of skin biopsy of two patients with Sweet’s syndrome, showing
clonal leukemic cytogenetic abnormality in the skin-infiltrating neutrophils. HES staining of the skin biopsy and FISH study of patient 11 with acute
myeloid leukemia (AML) showing 45,X,-Y(14)/46,XY(6) karyotype and Sweet’s syndrome (a, b), and patient 1 with AML showing complex karyotype with
5q- deletion and Sweet’s Syndrome (c, d). In figure b, the red probe recognizes the Y chromosome in Yp11.1-q11.1 and the green probe is specific for
the X chromosome in Xp11.1-q11.1. The neutrophils of the infiltrate have lost the Y chromosome (white arrows), whereas the epithelial cells are XY (white
arrowheads). In figure d, the red probe recognizes the EGR1 in 5q31.1 and the green probe is the control in 5q15.3. The neutrophilic infiltrate show 5q- nuclei
(white arrowheads), whereas the epithelial cells show two red and green signals (upper left insert).
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study suggests that the differentiation
event occurs in the dermis. More studies
will be necessary to confirm this possi-
bility and to identify the local factors
involved in the MDS/AML differentia-
tion in the dermis, which might be of
therapeutic value. For example, it would
be of great interest to evaluate whether
local vitamin D production is involved
in the dermal differentiation of blastic
cells, as this hormone has been proven
to be a differentiating agent for AML
cells (Callens et al., 2010).
Hoˆpital Saint Louis approved this
study. Written, informed consent was
given by all the patients still alive when
we started this retrospective study
(2011). This study adheres to the
declaration of Helsinki principles.
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Table 1. Clinical and cytogenetic characteristics of the patients and results of the FISH study
Patient
Sex/
age
(years)
Hemato-
logical
malignancy Bone marrow cytogenetic
Dermatologic
diagnosis
Blastic
cells
on skin
biopsy
Absolute
neutrophil
count (G/l)
at the time
of skin
biopsy Probe
Clonality of the
skin-infiltrating
neutrophils
1 F, 74 AML 44-47,X,add(X)(q27),del(5)(q14q34),
del(7)(q21q35),8,dic(12;22)
(p11;p11), þ 13,[10],t(15;15)
(p10;p10),þ r(?)[23],þ del(12)(p11)[3],
þ r(?)[7],þmar ou r(?)[3][cp23]/
46,XX[2]
Sweet
syndrome
No 5.4 del 5q deletion probe
(EGR1) (Amplitech,
Compiegne, France)
Yes
2 M,31 AML 46,XY,t(11;19)(q23;p13)[22]/ 46,XY[2] Sweet
syndrome
No 2.5 MLL Breakapart probe
(Vysis Abbott, Chicago,
IL)
Yes
3 M,39 AML 45,X,-Y,t(8;21)(q22;q22)[19] 46,XY[1] Sweet
syndrome
Yes 1.3 AML1 Breakapart probe
(Vysis Abbott)
Not
interpretable
4 M,74 MDS 47,XY,þ8[7] Sweet
syndrome
No 3.2 Cep 8 SpectrumOrange
(Vysis Abbott)
Yes
5 F,53 APL No karyotype, PML–RARA RT–PCR
positive
Sweet
syndrome
Yes 1.7 LSI PML–RAR dual color
dual fusion (Vysis Abbott)
Not
interpretable
6 M, 66 AML 46,XY,del(11)(q13qter)[18]/46,XY[2] Sweet
syndrome
No o0.1 MLL Breakapart probe
(Vysis Abbott)
Yes
7 M, 72 AML 46,XY,der(2)r(2;11)(p21q37;q23q25),
der(11)t(2;11)(p21;q23)[20]
Sweet
syndrome
No 2.1 MLL Breakapart probe
(Vysis Abbott)
No
8 F, 76 AML 49,XX,del(7)(q11),þ8,þ13, inv(16)
(p13;q23),þ 21[23]
Neutrophilic
eccrine
hydradenitis
No 0.4 Cep 8 SpectrumOrange
(Vysis Abbott)
Not
interpretable
9 F, 71 AML 46,XX,del(5)(q14q3?2)[13]/46,idem,?
del(20)(q12)[2]/46,XX[1]
Pyoderma
gangrenosum
No 4.6 del 5q deletion
probe(EGR1) (Amplitech)
Yes
10 M, 69 CMML 46,XY,del(20)(q1?2q1?3)[20] Sweet
syndrome
No 5 Del(20q) (PTPRT20q12/
20q11)(Kreatech,
Durham, North Carolina)
Yes
11 M, 69 AML 45,X,-Y[14]/46,XY[6] Sweet
syndrome
No o0.1 Dual labeled X&Y probe
(Cytocell, Cambridge,
UK)
Yes
12 F, 75 AML 47,XX,þ8[7]/46,XX[20] Sweet
syndrome
Yes 0.9 Cep 8 SpectrumOrange
(Vysis Abbott)
No
13 F,52 APL 46,XX,t(15;17)(q22;q21)[8]/ 46,XX[8] Sweet
syndrome
No 1 LSI PML–RAR dual color
dual fusion (Vysis Abbott)
No
14 M, 65 AML 47,XY,þ add(8)(q23),del(9) (q2?1q33),
der(15)t(1;15)(q2?4;p1?1)
[9]/ 46,XY[11]
Sweet
syndrome
Yes N.D. Cep 8 SpectrumOrange
(Vysis Abbott)
Yes
Abbreviations: AML, acute myeloid leukemia; APL, acute promyelocytic leukemia; CMML, chronic myelomonocytic leukemia; FISH, fluorescent in situ
hybridization; MDS, myelodysplastic syndrome; N.D., not determined; RT–PCR, reverse transcriptase–PCR.
FISH results were defined as positive if the same medullar cytogenetic anomaly was found in the neutrophils infiltrating the skin.
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